Hotta Tomomitsu | Department Of Hematology Molecular Medicine Unit Atomic Disease Institute Nagasaki University Gradua

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size : a report by the Nagasaki CML Study Group
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study
Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol
Rapid isolation of viral integration site reveals frequent integration of HTLV-1 into expressed loci
Phase III Study of Ranimustine, Cyclophosphamide, Vincristine, Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple Myeloma : A Japan Clinical Oncology Group Study, JCOG 9301
Successful cord blood transplantation for mycosis fungoides.
Imatinib Provides Durable Molecular and Cytogenetic Responses in a Practical Setting for Both Newly Diagnosed and Previously Treated Chronic Myelogenous Leukemia : A Study in Nagasaki Prefecture, Japan
Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein : a novel in vitro model of the growth of acute ATL cells
Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma : Japan Clinical Oncology Group study 9004
A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma : Japan Clinical Oncology Group Study 9002
Multicenter Prospective Study of Interferon α versus Allogeneic Stem Cell Transplantation for Patients with New Diagnoses of Chronic Myelogenous Leukemia
Possible Attenuation of Fas-Mediated Signaling by Dominant Expression of Caspase-8 Aberrant Isoform in Adult T-Cell Leukemia Cells
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade^【○!R】, ICL670) in patients with transfusion-dependent anemias and iron-overload : a Phase I study in Japan
Clonality analysis of granulocytes and T lymphocytes in healthy females by the PCR-based HUMARA method
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
IgD monoclonal gammopathy of undetermined significance
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
Allogeneic hematopoietic stem cell transplantation for ATL with central nervous system involvement : The Nagasaki Transplant Group experience
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95

もっと見る

スポンサーリンク